Search

Your search keyword '"Lydie Porte"' showing total 5 results
Start Over Author "Lydie Porte" Topic business
5 results on '"Lydie Porte"'

1. Dangerous Liaisons: Pelvic Variant of Lemierre Syndrome by Right Common Iliac Vein Thrombophlebitis After Sexual Intercourse

Author

Ludwig Duazo Cassin, Fabien Vidal, Olivier Parant, Helene Pol, Martin Baujat, Paul Guerby, Elodie Chantalat, Amanda Tournemire, and Lydie Porte

Subjects
0301 basic medicine, medicine.medical_specialty, Adolescent, Radiography, 030106 microbiology, Right common iliac vein, Iliac Vein, Thrombophlebitis, Pelvis, 03 medical and health sciences, 0302 clinical medicine, X ray computed, medicine, Humans, Lemierre Syndrome, Lung Abscess, business.industry, Coitus, Obstetrics and Gynecology, General Medicine, medicine.disease, Sexual intercourse, Fusobacterium necrophorum, 030220 oncology & carcinogenesis, Fusobacterium Infections, Female, Radiography, Thoracic, Radiology, business, Tomography, X-Ray Computed
Published
2017

2. Quinine unbound concentration is the best marker for therapeutic drug monitoring

Author

Didier Concordet, Michel Lavit, Etienne Chatelut, Patrick Seraissol, François Fraissinet, Peggy Gandia, Carlos de Pablos-Martinez, Antoine Berry, Lydie Porte, Institut Fédératif de Biologie - Laboratoire de Pharmacocinétique et Toxicologie, Centre Hospitalier Universitaire de Purpan (CHU Purpan), Département des Maladies Infectieuses, CHU Grenoble, Individualisation des traitements des cancers ovariens (ITCO), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer Toulouse - Oncopôle (IUCT), ToxAlim (ToxAlim), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole d'Ingénieurs de Purpan (INPT - EI Purpan), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA), Institut Fédératif de Biologie - Laboratoire de Pharmacologie et Toxicologie, Institut Fédératif de Biologie - Laboratoire de Pharmacocinétiqueet et Toxicologie, and Institut Fédératif de Biologie - Laboratoire de Pharmacocinétique etToxicologie

Subjects
Unbound fraction, [SDV]Life Sciences [q-bio], Pharmacology, Therapeutic drug monitoring, 030226 pharmacology & pharmacy, Antimalarials, 03 medical and health sciences, 0302 clinical medicine, Area under curve, parasitic diseases, Humans, Medicine, Pharmacology (medical), Quinine, Chromatography, medicine.diagnostic_test, business.industry, medicine.disease, Malaria, 3. Good health, Fraction libre, Area Under Curve, 030220 oncology & carcinogenesis, Drug Monitoring, business, Suivi pharmacologique thérapeutique, Protein Binding, medicine.drug
Abstract

Quinine monitoring should be based on unbound concentration due to variable unbound fraction in malaria patients.

Published
2016

3. Quinine unbound concentration has to be used for therapeutic drug monitoring

Author

Michel Lavit, Patrick Seraissol, Carlos de Pablos-Martinez, Etienne Chatelut, Peggy Gandia, Antoine Berry, Lydie Porte, François Fraissinet, Didier Concordet, Institut Fédératif de Biologie - Laboratoire de Pharmacocinétique et Toxicologie, Centre Hospitalier Universitaire de Purpan (CHU Purpan), Département des Maladies Infectieuses, CHU Grenoble, Institut Universitaire du Cancer Toulouse - Oncopôle (IUCT), ToxAlim (ToxAlim), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole d'Ingénieurs de Purpan (INPT - EI Purpan), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)

Subjects
Male, [SDV]Life Sciences [q-bio], Plasma protein binding, Pharmacology, 030226 pharmacology & pharmacy, Antimalarials, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Pharmacology (medical), Malaria, Falciparum, ComputingMilieux_MISCELLANEOUS, Quinine, medicine.diagnostic_test, business.industry, Therapeutic drug monitoring, 030220 oncology & carcinogenesis, Female, Drug Monitoring, business, Malaria falciparum, Protein Binding, medicine.drug
Abstract

International audience

Published
2016

4. Giant Cell Arteritis and Spinal Cord Compression: An Overlap Syndrome?

Author

Leonardo Astudillo, Philippe Arlet, Lydie Porte, Sophie Le Guellec, Emmanuelle Uro-Coste, I. Catalaa, S. Ollier, Bertrand Couret, Patrice Massip, and Laurent Sailler

Subjects
Male, Pathology, medicine.medical_specialty, Biopsy, Giant Cell Arteritis, Thoracic Vertebrae, Diagnosis, Differential, Central nervous system disease, Spinal cord compression, Humans, Medicine, Glucocorticoids, Aged, Anti-neutrophil cytoplasmic antibody, medicine.diagnostic_test, business.industry, Meninges, Overlap syndrome, Syndrome, General Medicine, medicine.disease, Magnetic Resonance Imaging, Giant cell arteritis, medicine.anatomical_structure, Drug Therapy, Combination, Female, Tomography, X-Ray Computed, business, Vasculitis, Spinal Cord Compression, Immunosuppressive Agents, Follow-Up Studies
Abstract

We describe 2 patients with spinal cord compression that occurred in the course of biopsy-proven giant cell arteritis (GCA). One case was due to an epidural tumorlike inflammatory lesion, the other to a concentric inflammatory thickening of the meninges. Both patients were highly corticodependent; they had low-titer anti-neutrophil cytoplasmic antibodies but no antimyeloperoxidase or antiproteinase 3 autoantibodies. The diagnosis was established by surgical biopsy. The histological pattern was reminiscent of Wegener granulomatosis. Both patients experienced relapse, despite high doses of corticosteroids, and experienced remission after the introduction of cyclophosphamide. Intravenous immunoglobulin perfusions were added for 1 patient. To our knowledge, spinal cord compression by a spinal pseudotumor or inflammatory meningitis has not been reported in the course of GCA. An overlap syndrome between GCA and Wegener granulomatosis is discussed.

Published
2006

5. Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy

Author

Jacques Gasnault, Dominique Costagliola, Houria Hendel-Chavez, Anne Dulioust, Sophie Pakianather, Anne-Aurélie Mazet, Marie-Ghislaine de Goer de Herve, Rémi Lancar, Anne-Sophie Lascaux, Lydie Porte, Jean-François Delfraissy, Yassine Taoufik, and ANRS 125 Trial Team

Subjects
Adult, Male, Oncology, Cart, medicine.medical_specialty, Enfuvirtide, HIV opportunistic infections, viruses, JC virus, lcsh:Medicine, HIV Infections, Viral diseases, medicine.disease_cause, Polymerase Chain Reaction, Leukoencephalopathy, Cerebrospinal fluid, Infectious Diseases of the Nervous System, HIV Fusion Inhibitors, Internal medicine, medicine, Humans, lcsh:Science, Immune Response, Survival rate, Univariate analysis, Multidisciplinary, business.industry, Progressive multifocal leukoencephalopathy, lcsh:R, Leukoencephalopathy, Progressive Multifocal, HIV, virus diseases, Middle Aged, medicine.disease, JC Virus, HIV Envelope Protein gp41, Peptide Fragments, nervous system, Anti-Retroviral Agents, Immunology, Medicine, Infectious diseases, lcsh:Q, Clinical Immunology, Female, business, Research Article, medicine.drug
Abstract

Background Progressive multifocal leukoencephalopathy (PML), a rare devastating demyelinating disease caused by the polyomavirus JC (JCV), occurs in severely immunocompromised patients, most of whom have advanced-stage HIV infection. Despite combination antiretroviral therapy (cART), 50% of patients die within 6 months of PML onset. We conducted a multicenter, open-label pilot trial evaluating the survival benefit of a five-drug cART designed to accelerate HIV replication decay and JCV-specific immune recovery. Methods and Findings All the patients received an optimized cART with three or more drugs for 12 months, plus the fusion inhibitor enfuvirtide during the first 6 months. The main endpoint was the one-year survival rate. A total of 28 patients were enrolled. At entry, median CD4+ T-cell count was 53 per microliter and 86% of patients had detectable plasma HIV RNA and CSF JCV DNA levels. Seven patients died, all before month 4. The one-year survival estimate was 0.75 (95% confidence interval, 0.61 to 0.93). At month 6, JCV DNA was undetectable in the CSF of 81% of survivors. At month 12, 81% of patients had undetectable plasma HIV RNA, and the median CD4+ T-cell increment was 105 per microliter. In univariate analysis, higher total and naive CD4+ T-cell counts and lower CSF JCV DNA level at baseline were associated with better survival. JCV-specific functional memory CD4+ T-cell responses, based on a proliferation assay, were detected in 4% of patients at baseline and 43% at M12 (P = 0.008). Conclusions The early use of five-drug cART after PML diagnosis appears to improve survival. This is associated with recovery of anti-JCV T-cell responses and JCV clearance from CSF. A low CD4+ T-cell count (particularly naive subset) and high JCV DNA copies in CSF at PML diagnosis appear to be risk factors for death. Trial Registration ClinicalTrials.gov NCT00120367

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results